inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at the time of screening who is being treated for covid-19. subjects must be screened within 48 hours (≤ 48 hours) of hospital admission. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr) or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration, including both of the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.) and/or clinical assessment (evidence of rales/crackles on the exam) with peripheral oxygen saturation by pulse oximetry (spo2) \<94% on room air 2. any one of the following related to covid-19: i. ferritin \> 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) \> 300 units per liter (u/l), iii. d-dimers \> reference range, or iv. c-reactive protein (crp) \> 40 milligram per liter (mg/l) 4. subjects provides informed consent prior to the initiation of any study procedures.

inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at the time of screening who is being treated for covid-19. subjects must be screened within 48 hours (≤ 48 hours) of hospital admission. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase \[rt\]-pcr) or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration, including both of the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.) and/or clinical assessment (evidence of rales/crackles on the exam) with peripheral oxygen saturation by pulse oximetry (spo2) \<94% on room air 2. any one of the following related to covid-19: i. ferritin \> 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) \> 300 units per liter (u/l), iii. d-dimers \> reference range, or iv. c-reactive protein (crp) \> 40 milligram per liter (mg/l) 4. subjects provides informed consent prior to the initiation of any study procedures.

inclusion criteria: hospitalized male or female subject ≥ 18 years of age at the time of screening who is being treated for covid-19. subjects must be screened within 48 hours (≤ 48 hours) of hospital admission. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr) or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. covid-19 illness (symptoms) of any duration, including both of the following: radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.) and/or clinical assessment (evidence of rales/crackles on the exam) with peripheral oxygen saturation by pulse oximetry (spo2) <94% on room air any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l) subjects provides informed consent prior to the initiation of any study procedures.

inclusion criteria: hospitalized male or female subject ≥ 18 years of age at the time of screening who is being treated for covid-19. subjects must be screened within 48 hours (≤ 48 hours) of hospital admission. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr) or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. covid-19 illness (symptoms) of any duration, including both of the following: radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.) and/or clinical assessment (evidence of rales/crackles on the exam) with peripheral oxygen saturation by pulse oximetry (spo2) <94% on room air any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l) subjects provides informed consent prior to the initiation of any study procedures.

inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at the time of screening who is being treated for covid-19. subjects must be screened within 48 hours (≤ 48 hours) of hospital admission. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr) or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration, including both of the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.) and/or clinical assessment (evidence of rales/crackles on the exam) with peripheral oxygen saturation by pulse oximetry (spo2) <94% on room air 2. any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l) 4. subjects provides informed consent prior to the initiation of any study procedures.

inclusion criteria: 1. hospitalized male or female subject ≥ 18 years of age at the time of screening who is being treated for covid-19. subjects must be screened within 48 hours (≤ 48 hours) of hospital admission. 2. has laboratory-confirmed novel coronavirus (sars-cov-2) infection as determined by qualitative polymerase chain reaction (pcr) (reverse transcriptase [rt]-pcr) or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. 3. covid-19 illness (symptoms) of any duration, including both of the following: 1. radiographic infiltrates by imaging (chest x-ray, computerized tomography (ct) scan, etc.) and/or clinical assessment (evidence of rales/crackles on the exam) with peripheral oxygen saturation by pulse oximetry (spo2) <94% on room air 2. any one of the following related to covid-19: i. ferritin > 400 nanogram per milliliter (ng/ml), ii. lactate dehydrogenase (ldh) > 300 units per liter (u/l), iii. d-dimers > reference range, or iv. c-reactive protein (crp) > 40 milligram per liter (mg/l) 4. subjects provides informed consent prior to the initiation of any study procedures.